XML 35 R14.htm IDEA: XBRL DOCUMENT
v3.19.3

Collaboration and Licensing Revenue | 9 Months Ended
--- | ---
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Collaboration and Licensing Revenue | Collaboration and Licensing Revenue The Company's collaborations and licensing agreements provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. At contract inception, the transaction price is typically the upfront payment received and is allocated to the single performance obligation. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation. The Company recognizes the reimbursement payments received for research and development services in the period when the services are performed. At the inception of each collaboration, the Company determines whether any milestone payments are probable and can be included in the transaction price. The milestone payments are typically not considered probable at inception and are therefore constrained. Royalties related to product sales will be recognized when sales have occurred since the royalties relate directly to the technology license granted in the agreement. The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with either majority-owned subsidiaries or equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and nine months ended September 30, 2019 and 2018.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
ZIOPHARM Oncology, Inc. | $ | 431 |  |  | $ | 4,826 |  |  | $ | 2,130 |  |  | $ | 13,626 |
Ares Trading S.A. | — |  |  | 1,576 |  |  | — |  |  | 7,525 |
Oragenics, Inc. | 231 |  |  | 705 |  |  | 615 |  |  | 867 |
Intrexon T1D Partners, LLC | — |  |  | 368 |  |  | — |  |  | 2,399 |
Intrexon Energy Partners, LLC | 823 |  |  | 1,329 |  |  | 2,596 |  |  | 3,345 |
Intrexon Energy Partners II, LLC | 293 |  |  | 754 |  |  | 1,217 |  |  | 1,685 |
Surterra Holdings, Inc. | 1,022 |  |  | — |  |  | 1,182 |  |  | — |
Genopaver, LLC | 494 |  |  | 689 |  |  | 1,186 |  |  | 3,076 |
Fibrocell Science, Inc. | 402 |  |  | 391 |  |  | 3,247 |  |  | 1,015 |
Persea Bio, LLC | 1,083 |  |  | 199 |  |  | 621 |  |  | 714 |
Harvest start-up entities (1) | 100 |  |  | 2,691 |  |  | 4,862 |  |  | 11,792 |
Other | 1,306 |  |  | 796 |  |  | 3,596 |  |  | 5,578 |
Total | $ | 6,185 |  |  | $ | 14,324 |  |  | $ | 21,252 |  |  | $ | 51,622 |
(1) | For the three and nine months ended September 30, 2019 and 2018, revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the nine months ended September 30, 2018, revenues recognized from collaborations with Harvest start-up entities also include Genten Therapeutics, Inc. and CRS Bio, Inc.
Except for the agreements discussed below, there have been no significant changes to the agreements with our collaborators and licensees in the nine months ended September 30, 2019. Surterra Collaboration In June 2019, the Company entered into an Exclusive Product Collaboration agreement ("Surterra EPC") with Surterra Holdings, Inc. ("Surterra") to advance Surterra's cannabinoid production at a reliable, efficient, cost-effective, and industrial scale utilizing the Company's yeast fermentation platform. Under the Surterra EPC, Surterra is responsible for the commercialization of products, including securing any regulatory approvals. Upon execution of the Surterra EPC, the Company received a technology access fee in the form of a $10,000 cash payment and common stock of Surterra valued at $4,530 as upfront consideration. The Company is entitled to developmental milestones for each target selected by Surterra up to a maximum of $68,000 for the achievement of all milestones for all targets as defined in the agreement. The Company is entitled to payments for research and development services provided pursuant to the agreement as well as single-digit royalties on quarterly gross sales of products developed. The Company's performance obligations terminate upon the acceptance of all deliverables for each target selected under the agreement, and the agreement may be terminated by either party in the event of a material breach as defined in the agreement or may be terminated voluntarily by Surterra upon 90 days written notice to the Company. Fibrocell Science Collaboration In April 2019, Fibrocell Science, Inc. ("Fibrocell"), a publicly traded cell and gene therapy company focused on disease affecting the skin and connective tissue and a related party, entered into a collaboration agreement with a third party to develop and commercialize a product in the field of the Company's ECC with Fibrocell ("Fibrocell ECC"). Pursuant to the terms of the Fibrocell ECC, the Company is entitled to 50% of sublicensing fees and received $3,750 during the nine months ended September 30, 2019. Deferred Revenue Deferred revenue primarily consists of consideration received for the Company's collaboration and licensing agreements. Deferred revenue consists of the following:
| September 30, 2019 |  | December 31, 2018
Collaboration and licensing agreements | $ | 74,431 |  |  | $ | 63,284 |
Prepaid product and service revenues | 3,054 |  |  | 2,933 |
Other | 1,639 |  |  | 3,547 |
Total | $ | 79,124 |  |  | $ | 69,764 |
Current portion of deferred revenue | $ | 12,764 |  |  | $ | 15,554 |
Long-term portion of deferred revenue | 66,360 |  |  | 54,210 |
Total | $ | 79,124 |  |  | $ | 69,764 |
The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of September 30, 2019 and December 31, 2018, including the estimated remaining performance period as of September 30, 2019.
| Average Remaining Performance Period (Years) |  | September 30, 2019 |  | December 31, 2018
ZIOPHARM Oncology, Inc. | 0.0 |  | $ | — |  |  | $ | 1,214 |
Oragenics, Inc. | 4.7 |  | 5,463 |  |  | 5,810 |
Intrexon Energy Partners, LLC | 4.5 |  | 8,362 |  |  | 10,267 |
Intrexon Energy Partners II, LLC | 5.2 |  | 12,843 |  |  | 14,060 |
Surterra Holdings, Inc. | 8.7 |  | 13,987 |  |  | — |
Genopaver, LLC | 4.5 |  | 789 |  |  | 1,175 |
Fibrocell Science, Inc. | 5.1 |  | 18,102 |  |  | 17,519 |
Persea Bio, LLC | 5.3 |  | 3,553 |  |  | 2,697 |
Harvest start-up entities (1) | 5.4 |  | 6,993 |  |  | 7,644 |
Other | 1.7 |  | 4,297 |  |  | 2,898 |
Total |  |  | $ | 74,389 |  |  | $ | 63,284 |
(1) As of September 30, 2019 and December 31, 2018, the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

X
- Definition The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -URI http://asc.fasb.org/topic&trid=5833765 + Details
Name: | us-gaap_CollaborativeArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration